e-learning
resources
Madrid 2019
Sunday, 29.09.2019
Comorbidities galore in respiratory patients
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Late Breaking Abstract - Antibiotic treatment in acute exacerbation of COPD: patient outcomes with amoxicillin vs. amoxicillin/clavulanic acid - Data from 38,820 outpatients.
K. Bagge (Hellerup, Denmark), F. Böetius Hertz (Herlev, Denmark), J. Victoria Eklöf (Hellerup, Denmark), P. Sivapalan (Hellerup, Denmark), J. Stæhr Jensen (Hellerup, Denmark)
Source:
International Congress 2019 – Comorbidities galore in respiratory patients
Session:
Comorbidities galore in respiratory patients
Session type:
Oral Presentation
Number:
287
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Bagge (Hellerup, Denmark), F. Böetius Hertz (Herlev, Denmark), J. Victoria Eklöf (Hellerup, Denmark), P. Sivapalan (Hellerup, Denmark), J. Stæhr Jensen (Hellerup, Denmark). Late Breaking Abstract - Antibiotic treatment in acute exacerbation of COPD: patient outcomes with amoxicillin vs. amoxicillin/clavulanic acid - Data from 38,820 outpatients.. 287
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results
Source: Eur Respir J 2012; 40: 17-27
Year: 2012
Late-breaking abstract: Moxifloxacin (MXF) vs amoxicillin/clavulanic acid (AMC) in acute exacerbations of COPD (AECOPD): Results of a large clinical trial with a novel endpoint
Source: Annual Congress 2011 - Mechanisms and outcomes of infective exacerbations of COPD
Year: 2011
Late Breaking Abstract - Adjunctive treatment with oral dexamethasone in adults hospitalised with community-acquired pneumonia: a randomised clinical trial
Source: Virtual Congress 2020 – ALERT: Infection in adults and children
Year: 2020
Short and long-term outcomes of moxifloxacin (MXF) compared to standard antibiotic treatment (STD) in acute exacerbations of chronic bronchitis (AECB): The MOSAIC study
Source: Eur Respir J 2003; 22: Suppl. 45, 566s
Year: 2003
Late Breaking Abstract - Azithromycin for acute COPD exacerbations requiring hospitalization – the BACE trial results
Source: International Congress 2018 – Clinical trials in COPD: new results
Year: 2018
Late Breaking Abstract - Effect of adjunctive tobramycin inhalation therapy in the treatment of ventilator-associated pneumonia: findings from the randomized VAPORISE trial
Source: International Congress 2019 – Recent developments in intensive care unit medicine
Year: 2019
Bacterial profile and antibiotic susceptibility from patients with exacerbation of COPD: 10 – years prospective study
Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections
Year: 2016
LATE-BREAKING ABSTRACT: Oral solithromycin has a favorable profile versus oral moxifloxacin for treatment of adult community-acquired pneumonia (CABP) in elderly patients and those with COPD or asthma
Source: International Congress 2015 – Respiratory infections: from basic science to clinical issues
Year: 2015
Late Breaking Abstract - Prolonged azithromycin maintenance treatment in patients with COPD, a follow-up of the COLUMBUS trial
Source: International Congress 2019 – Blood eosinophils and more in airway diseases
Year: 2019
Debate: Antibiotic treatment is contraindicated in acute bronchitis - CON
Source: Annual Congress 2008 - PG1 - EU GRACE network full-day course: Antibiotics or not: from acute bronchitis to acute exacerbation of chronic bronchitis
Year: 2008
Late Breaking Abstract - Duration of amoxicillin-clavulanate for protracted bacterial bronchitis in children: a randomized controlled trial
Source: Virtual Congress 2020 – ALERT: Infection in adults and children
Year: 2020
Late Breaking Abstract - Compare outcomes between COPD patients treated with Tiotropium/Olodaterol (TIO/OLO) and other fixed-dose LAMA/LABAs
Source: Virtual Congress 2020 – COPD and the impact of comorbidities
Year: 2020
Health status following an acute exacerbation of chronic bronchitis (AECB) is better in patients receiving gemifloxacin compared with clarithromycin
Source: Eur Respir J 2001; 18: Suppl. 33, 542s
Year: 2001
Late Breaking Abstract - Changes in respiratory symptoms during 48 weeks treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies
Source: Virtual Congress 2020 – ALERT: Infection in adults and children
Year: 2020
Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis: the BEST-2 trial
Source: International Congress 2018 – Bronchiectasis: new insights in diagnosis and treatment
Year: 2018
Short-term efficacy of moxifloxacin (MXF) compared to standard antibiotic treatment (STD) in acute exacerbations of chronic bronchitis (AECB): A multivariate analysis from the MOSAIC study
Source: Eur Respir J 2003; 22: Suppl. 45, 351s
Year: 2003
Timing of antibiotic administration and outcomes for patients with community-acquired pneumonia (CAP). NAC-CV Study
Source: Eur Respir J 2006; 28: Suppl. 50, 349s
Year: 2006
Greatest International ANti-infective Trial (GIANT) – the German cohort: moxifloxacin treatment provides short- and long-term benefits in AECB patients
Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients
Year: 2006
Treatment failure of hospitalized patients with COPD exacerbation using systemic corticosteroids plus antibiotics: Role of early inflammatory predictors
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept